The HOX Hypothesis: A Novel Approach To Targeted Cancer Therapy
Emerging Company Profile: With a Phase I clinical trial starting in Q3 and Series A funding to raise, HOX Therapeutics is taking a step out of the shadows of academia to develop its novel drug candidates in brain and prostate cancer. CEO Karl Keegan spoke to Scrip about what is next for the UK company.
You may also be interested in...
Changed world, new priorities and ways of working? Senior medtech CEOs put their finger on how altered attitudes and new expectations from staff, especially the younger entrants into corporate life, are influencing management styles, now and in the future.
Swiss-based Rejuveron’s diversified platform of longevity biotechs addresses key hallmarks of aging, with the goal of helping people to age better and live longer with reduced burden of age-related diseases. CEO Matthias Steger discusses the firm’s vision and the road ahead.